{
  "abstract": "Background In MycarinG ( NCT03971422; Phase 3), adults with generalised myasthenia gravis (gMG) received one 6-week rozanolixizumab treatment cycle. All patients who enrolled in MG0007 (NCT04650854; open-label extension) received one further treatment cycle with subsequent need-based cycles initiated at the investigator’s discretion. Thus, cycle number and treatment-free intervals varied per patient.Methods Clustering analysis was conducted on the number of cycles per year (CPY) in patients with ≥1 cycle from MycarinG and MG0007 (data cut-off: 08 July 2022). Baseline characteristics were assessed for association with CPY using multivariate regression models. Treatment-emergent adverse events were compared among clusters.Results Balanced clustering and optimal goodness-of-fit was achieved using three clusters to describe CPY (low: <2.59; medium: 2.59–4.64; high: >4.64). Mean (standard deviation) CPY in each cluster was 1.50 (0.53, n=74), 3.59 (0.60, n=64) and 5.82 (0.72, n=50), respectively. Overall, baseline characteristics were balanced between clusters and were not predictive of CPY for patients. Rozanolixizumab was generally well tolerated across the clusters.Conclusions These three treatment clusters demonstrate that rozanolixizumab cycle cadence varies between patients, from 1–7 CPY. This suggests an individualised approach to rozanolixizumab treatment based on each patient’s own gMG experience, as the study included a broad, adult gMG population.rowan.orme@ucb.com",
  "authors": [
    {
      "affiliations": [
        "UCB, Slough, UK"
      ],
      "name": "Orme Rowan"
    },
    {
      "affiliations": [
        "Department of Neurology, University of California, Irvine, Orange, CA, USA"
      ],
      "name": "Habib Ali A"
    },
    {
      "affiliations": [
        "Department of Neurology, University of Lübeck, Lübeck, Germany"
      ],
      "name": "Grosskreutz Julian"
    },
    {
      "affiliations": [
        "Pasteur 2 Hospital, Centre Hospitalier Universitaire de Nice, Nice, France"
      ],
      "name": "Sacconi Sabrina"
    },
    {
      "affiliations": [
        "Hanamaki General Hospital, Hanamaki, Japan"
      ],
      "name": "Utsugisawa Kimiaki"
    },
    {
      "affiliations": [
        "Department of Neurology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark"
      ],
      "name": "Vissing John"
    },
    {
      "affiliations": [
        "Department of Neurology, University of South Florida Morsani College of Medicine, Tampa, FL, USA"
      ],
      "name": "Vu Tuan"
    },
    {
      "affiliations": [
        "UCB, Monheim, Germany"
      ],
      "name": "Boehnlein Marion"
    },
    {
      "affiliations": [
        "UCB, Slough, UK"
      ],
      "name": "Grimson Fiona"
    },
    {
      "affiliations": [
        "UCB, Slough, UK"
      ],
      "name": "et al"
    }
  ],
  "title": "1 Rozanolixizumab treatment patterns in patients with generalised myasthenia gravis: post hoc analysis",
  "uid": "324afe34-9449-5320-b4d5-d5578783e995"
}